Literature DB >> 3679286

A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets.

F A Spring1, P A Judson, G L Daniels, S F Parsons, G Mallinson, D J Anstee.   

Abstract

A new human erythrocyte glycoprotein has been identified by immunoblotting with murine monoclonal antibodies under non-reducing conditions. The glycoprotein has a MW of 70,000 and carries Cromer-related blood group antigens. The monoclonal antibodies also react with normal peripheral blood leucocytes and platelets and several haemopoietic cell lines. The glycoprotein has a reduced MW after sialidase treatment. The MW is markedly reduced in Tn erythrocyte membranes and slightly increased in Cad erythrocyte membranes. These results suggest that the glycoprotein has a substantial content of O-glycans. The glycoprotein appears to be absent from, or grossly altered in, the erythrocytes of two individuals with the rare Inab phenotype.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3679286      PMCID： PMC1453983     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  33 in total

1.  IMMUNOCHEMICAL STUDIES OF THE RH SYSTEM. I. ISOLATION AND CHARACTERIZATION OF ANTIBODIES.

Authors:  S KOCHWA; R E ROSENFIELD
Journal:  J Immunol       Date:  1964-05       Impact factor: 5.422

2.  An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia.

Authors:  A T Nurden; J P Caen
Journal:  Br J Haematol       Date:  1974-10       Impact factor: 6.998

3.  Scoring of hemagglutination reactions.

Authors:  W L Marsh
Journal:  Transfusion       Date:  1972 Sep-Oct       Impact factor: 3.157

4.  Isolation and characterization of plasma membranes from human blood platelets.

Authors:  A J Barber; G A Jamieson
Journal:  J Biol Chem       Date:  1970-12-10       Impact factor: 5.157

5.  [Herediatry dominant polyagglutinability: private antigen (Cad) corresponding to a public antibody and a lectin of Dolichos biflorus].

Authors:  P Cazal; M Monis; J Caubel; J Brives
Journal:  Rev Fr Transfus       Date:  1968-10-03

6.  Two apparently healthy Japanese individuals of type MkMk have erythrocytes which lack both the blood group MN and Ss-active sialoglycoproteins.

Authors:  E Tokunaga; S Sasakawa; K Tamaka; H Kawamata; C M Giles; E W Ikin; J Poole; D J Anstee; W Mawby; M J Tanner
Journal:  J Immunogenet       Date:  1979-12

7.  Demonstration of T-transferase deficiency in Tn-polyagglutinable blood samples.

Authors:  J P Cartron; G Andreu; J Cartron; G W Bird; C Salmon; A Gerbal
Journal:  Eur J Biochem       Date:  1978-12-01

Review 8.  Tn-polyagglutination.

Authors:  G W Bird
Journal:  Rev Fr Transfus Immunohematol       Date:  1976-03

9.  Monoclonal antibody to a human brain-granulocyte-T lymphocyte antigen probably homologous to the W 3/13 antigen of the rat.

Authors:  R Dalchau; J Kirkley; J W Fabre
Journal:  Eur J Immunol       Date:  1980-10       Impact factor: 5.532

10.  Chemical characterisation of the Thy-1 glycoproteins from the membranes of rat thymocytes and brain.

Authors:  A N Barclay; M Letarte-Muirhead; A F Williams; R A Faulkes
Journal:  Nature       Date:  1976-10-14       Impact factor: 49.962
View more
  15 in total

1.  Human leucocyte surface glycoprotein CDw44 and lymphocyte homing receptor are identical molecules.

Authors:  I Stefanová; I Hilgert; V Bazil; H Kristofová; V Horejsí
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

2.  Identification and immunochemical characterization of the human erythrocyte membrane glycoproteins that carry the Xga antigen.

Authors:  R Herron; G A Smith
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

3.  Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.

Authors:  D M Lublin; E S Thompson; A M Green; C Levene; M J Telen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  The Dr hemagglutinin, afimbrial adhesins AFA-I and AFA-III, and F1845 fimbriae of uropathogenic and diarrhea-associated Escherichia coli belong to a family of hemagglutinins with Dr receptor recognition.

Authors:  B Nowicki; A Labigne; S Moseley; R Hull; S Hull; J Moulds
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

Review 5.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

6.  Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.

Authors:  C G Tate; M Uchikawa; M J Tanner; P A Judson; S F Parsons; G Mallinson; D J Anstee
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

7.  Presence of the Dr receptor in normal human tissues and its possible role in the pathogenesis of ascending urinary tract infection.

Authors:  B Nowicki; L Truong; J Moulds; R Hull
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

8.  Complement regulatory proteins in early human fetal life: CD59, membrane co-factor protein (MCP) and decay-accelerating factor (DAF) are differentially expressed in the developing liver.

Authors:  K L Simpson; J M Houlihan; C H Holmes
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

9.  New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.

Authors:  A Fletcher; J A Bryant; B Gardner; P A Judson; F A Spring; S F Parsons; G Mallinson; D J Anstee
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

10.  Rapid cyclic changes in density and accessibility of endometrial ligands for Escherichia coli Dr fimbriae.

Authors:  A K Kaul; D Kumar; M Nagamani; P Goluszko; S Nowicki; B J Nowicki
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.